Sulphathiazole Sodium
|
HS Code |
602385 |
| Chemical Formula | C9H8N3NaO2S2 |
| Molar Mass | 299.30 g/mol |
| Appearance | Yellow - white crystalline powder |
| Solubility | Soluble in water |
| Ph In Solution | 9.5 - 11.0 (1% solution) |
| Odor | Odorless |
| Melting Point | ~270 °C (decomposes) |
| Storage Condition | Stored in a cool, dry place |
| Stability | Stable under normal conditions |
| Usage | Antibacterial agent |
As an accredited Sulphathiazole Sodium factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Sulphathiazole Sodium in blister packs, each containing 10 tablets. |
| Shipping | Sulphathiazole Sodium is shipped in well - sealed containers, compliant with chemical transportation regulations. Care is taken to prevent moisture and contamination during transit to maintain product integrity. |
| Storage | Sulphathiazole Sodium should be stored in a cool, dry place. Keep it away from direct sunlight and sources of heat to prevent degradation. Store in a well - sealed container to avoid moisture absorption, which could affect its quality. Ensure the storage area is well - ventilated and separated from incompatible substances to maintain its chemical integrity. |
|
```html Pre-mix granulation and the critical role of carrier particle size distribution Production-scale incorporation of sulphathiazole sodium into animal feed begins with wet granulation on a high-shear mixer-granulator equipped with a chopper speed of 1,500–3,000 rpm and impeller tip speed of 4–8 m/s. The active is blended with a lactose monohydrate or pregelatinised starch carrier where the d50 of the carrier must fall between 100 µm and 250 µm to minimise segregation during pneumatic conveying. A binder solution of povidone K30 at 3–5% w/w in purified water is sprayed at a rate of 0.5–1.2 kg/min for a 200-litre bowl, targeting granule endpoint moisture of 8–12% as determined by loss-on-drying at 105 °C. Over-wetting beyond 14% moisture triggers irreversible agglomeration and causes caking in the subsequent fluid-bed dryer set to inlet air temperature 60–70 °C and air velocity 1.8–2.5 m/s. The dried granules are milled through a 1.0 mm conidur screen and sieved to collect the 200–800 µm fraction; fines <100 µm are recycled at ≤15% of fresh feed to avoid dust explosion hazards. Final blends are adjusted to deliver sulphathiazole sodium at 100–250 g per metric ton of complete feed, corresponding to daily intake of 10–20 mg/kg bodyweight in grower pigs. Homogeneity must satisfy the ±10% acceptance criteria of Ph.Eur. 2.9.40 Uniformity of Dosage Units, with assay values confirmed by HPLC using a C18 column, mobile phase acetonitrile/0.05 M phosphate buffer pH 3.0 (25:75 v/v), and detection at 264 nm. This medicated pre-mix is typically filled into 25 kg multi-wall paper sacks with an inner PE liner, labelled in compliance with EU Regulation 2019/4 on medicated feed, and carries a withdrawal period of at least 7 days before slaughter for pigs and 5 days for broilers in markets where sulphathiazole residues are monitored under Commission Regulation (EU) No 37/2010, which sets the MRL for the sum of sulphathiazole and its metabolites at 100 µg/kg in muscle, fat, liver, and kidney of porcine and poultry species. What Limits the Solubility of Sulphathiazole Sodium in Drinking Water Administration Systems?The solubility of sulphathiazole sodium in water at 20 °C exceeds 50 g/L, yet the practical upper concentration for proportioner-mediated delivery is capped at 1–2 g/L to avoid precipitation in hard water containing calcium ions above 150 mg/L as CaCO₃. When reconstituted in farm well water with total hardness >250 mg/L, the sodium salt undergoes counter-ion exchange yielding the less soluble free acid form which crystallises as fine needles that obstruct the 0.5 mm orifice of dosing pumps. To mitigate this, commercial water-soluble powders incorporate a sequestering agent—typically sodium hexametaphosphate at 5–10% w/w of the formulated product—and are buffered with anhydrous sodium carbonate to maintain a solution pH between 8.5 and 10.0. At pH <8.0, precipitation half-life drops below 4 hours in static conditions. Field experience with 1,000-litre header tanks on broiler farms shows that without continuous agitation via a recirculation loop delivering a flow rate of 20–30 L/min, sedimentation of the active occurs within 6 hours, resulting in under-dosing of the last birds in the line. The target medicated water is prepared as a stock solution diluted 1:100 or 1:200 via a positive-displacement dosing pump, achieving a final drinking water concentration of 0.5–1.0 g/L for a therapeutic course lasting 3–5 days. Efficacy against Escherichia coli O78 in experimentally infected broilers, according to a published challenge study model, demands peak plasma concentrations >30 µg/mL, which requires a steady water intake of 180–220 mL/bird/day; higher ambient temperatures above 32 °C increase water consumption, diluting intake and necessitating concentration adjustment based on real-time water meter readings. The product must be clearly labelled with the instruction to prepare fresh solution daily and to flush the system with clean water for 30 minutes after the medication period to remove residual high-pH solution that can corrode galvanised steel nipples over time. In intensive aquaculture systems, the administration of sulphathiazole sodium to rainbow trout (Oncorhynchus mykiss) stocks affected by furunculosis caused by Aeromonas salmonicida follows a distinct oral top-dressing protocol on extruded floating feed. The medicated feed is manufactured by coating the pellets with a suspension of sulphathiazole sodium in fish oil or a fish oil/soy lecithin mixture at 0.5–1.0% w/w coating rate. The coating is applied in a vacuum coater operating at –0.6 bar and 35 °C, with a holding time of 8–12 minutes to ensure penetration of the active into the pellet pores. The dosage is calibrated to 100–150 mg/kg biomass per day for 10–14 consecutive days, a regimen that must be initiated only when water temperature is between 10 °C and 18 °C because the metabolic clearance rate in trout halves for every 5 °C drop below 10 °C, raising the risk of tissue residue violation. The marker residue in fish muscle is measured as the parent compound, with an MRL of 100 µg/kg under Japan’s Positive List System and Codex Alimentarius CAC/GL 71-2009 guidelines; a withdrawal period of 500 degree-days is commonly observed before harvest. Effluent from medicated raceways must not be discharged untreated into natural watercourses; an approved practice involves holding the water in a settlement lagoon for a minimum of 72 hours under natural photolysis and microbial degradation, with sulphathiazole sodium concentration verified to be below 1 µg/L at the point of release using LC-MS/MS with a limit of quantification of 0.1 µg/L. Operators are advised not to vaccinate fish concurrently with the treatment course, as the bacteriostatic action of sulphathiazole sodium can interfere with the live attenuated vaccine replication, rendering the vaccination ineffective. Injectable Formulation of Sulphathiazole Sodium: Osmolality and Tissue Tolerance ConstraintsA sterile injectable solution of sulphathiazole sodium is prepared at a concentration of 200 mg/mL in a vehicle composed of water for injection, propylene glycol (35–40% v/v), and benzyl alcohol (2% v/v) as a preservative, with the pH adjusted to 8.0–9.0 using 1N sodium hydroxide. The formulation requires terminal sterilisation by autoclaving at 121 °C for 15 minutes, a process that must be validated to confirm that the peak temperature inside the sealed Type I glass vials reaches at least 121 °C for a minimum of 12 minutes with an F₀ value ≥15. Because of the hypertonic nature of the solution (calculated osmolality 1,800–2,400 mOsmol/kg), intramuscular injection in calves is limited to a maximum volume of 10 mL per site, and the product must be injected deep into the gluteal muscle using an 18-gauge, 1.5-inch needle, with the site massaged for 30 seconds post-injection to prevent localised necrosis. Repeated injections are spaced at 12-hour intervals, and the manufacturer’s datasheet typically stipulates an upper limit of 5 consecutive days of therapy. At the injection site, a residue depletion study according to VICH GL48 guidelines demonstrates that the sulphathiazole sodium concentration declines below the 100 µg/kg MRL after 21 days, thus setting the withdrawal period for meat at 28 days. The product should not be administered intravenously undiluted because the propylene glycol content can cause haemolysis and cardiac arrhythmia in bovine species; if intravenous administration is clinically necessary, the dose must be diluted to a 1:10 ratio in sterile normal saline and infused at a rate not exceeding 5 mL/minute. Ophthalmic and Dermal Semi-solid Preparations and the Necessity for Preservative SynergySulphathiazole sodium is incorporated into a sterile ophthalmic ointment base consisting of white petrolatum and liquid paraffin in a ratio of 70:30, with the active triturated aseptically through a 100-mesh screen to achieve a final concentration of 5% w/w. The anhydrous base suppresses recrystallisation of the sodium salt into larger needle-like crystals that would cause corneal abrasion; particle size is controlled to <10 µm as verified by microscopic examination at 400× magnification under a calibrated polarising microscope. The ointment is filled into 3.5 g single-use, gamma-sterilised aluminium tubes lined with an epoxy-resin internal coating that is resistant to the alkaline pH micro-environment (pH 8.5–9.5 on hydration). In the treatment of Infectious Bovine Keratoconjunctivitis (IBK) caused by Moraxella bovis, the ointment is applied twice daily for 7 days, and a protective periocular covering of petrolatum is applied to prevent dust adherence. For dermal applications, a water-removable base made of cetyl alcohol (5% w/w), white wax (12% w/w), sodium lauryl sulphate (1% w/w), and water is preferred, giving a sulphathiazole sodium concentration of 10% w/w. This cream formulation is used off-label for the topical management of dermatophilosis in sheep under high-humidity conditions; however, published data for this specific configuration is limited to case reports from the 1970s and commercial availability is restricted in the EU due to a lack of modern statutory maximum residue limit evaluations for topical routes on fibre-producing animals. Compounding pharmacists must note that combination with chlorhexidine gluconate in the same preparation leads to rapid precipitation of the sulphonamide and must be avoided. Sulphonamide Intermediates and Analytical Reference StandardsBeyond direct therapeutic use, sulphathiazole sodium is supplied as a pharmaceutical intermediate for the synthesis of silver sulphathiazole, a topical burn cream active. In this synthesis, an aqueous solution of sulphathiazole sodium (20% w/v) is reacted with an equimolar amount of silver nitrate under controlled red LED light to minimise photodecomposition, yielding a cream-coloured precipitate that is filtered, washed with acetone, and dried under vacuum at 40 °C for 24 hours. The stoichiometric conversion rate exceeds 98% when the pH is maintained at 7.0–7.5 using a 0.1 M ammonium acetate buffer. Additionally, sulphathiazole sodium is employed as a certified reference standard, compliant with Ph.Eur. reference standard monograph 09/2024:0403000, where the purity is certified at 99.5% on a dried basis through mass balance calculation subtracting total related substances (<0.5%) determined by HPLC and residual solvents (ethanol ≤500 ppm, isopropyl alcohol ≤200 ppm) by headspace GC-FID. These standards are packaged in 100 mg amber vials under argon overlay and recommended for storage at 2–8 °C with a retest date of 4 years when unopened. The use as a standard in method validation for sulphonamide residue screening in honey, according to AOAC Official Method 2001.03, requires a stock solution of 1 mg/mL in acetonitrile/water (1:1 v/v), which remains stable for one month at –20 °C. |
Competitive Sulphathiazole Sodium prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Sulphathiazole Sodium (CAS 144-74-1, molecular formula C9H8N3NaO2S2, molecular weight 277.30 g·mol−1) is the sodium salt monohydrate of the sulfonamide bacteriostatic agent sulfathiazole. The compound appears as a white to faintly yellow crystalline powder, freely soluble in water (1 g in 2 mL at 25°C) and sparingly soluble in ethanol. Unlike the free acid form—which requires alkaline pH adjustment for dissolution—the sodium salt yields solutions with a native pH of 8.0–10.0 (aqueous 10% w/v) and bypasses the gastrointestinal pH-dependent solubility bottleneck that limits oral bioavailability of the parent sulfathiazole. Historical human pharmacopoeia monographs have been largely superseded; contemporary manufacture targets the veterinary drug premix, oral powder, and injectable concentrate sectors, with primary production volumes directed at swine and poultry respiratory and enteric indications.
The heterocyclic substituent on the sulfanilamide core governs clinically relevant pharmacokinetic divergence. Sulphathiazole incorporates a 1,3-thiazole ring, whereas sulfadiazine carries a pyrimidine ring and sulfachlorpyridazine a 3-chloro-6-methoxypyridazine moiety. This substitution shifts the acid dissociation constant: the sulfonamido proton pKa of sulfathiazole is approximately 7.1 at 25°C (measured potentiometrically per EP 2.2.3), compared to 6.5 for sulfadiazine and 5.9 for sulfamethazine. The higher pKa reduces the proportion of the lipid-soluble non-ionized fraction at physiological pH approximately 7.4, marginally decelerating passive diffusion across the enteric epithelium yet enhancing renal clearance once filtered. Protein binding, determined by equilibrium dialysis, ranges from 55–70% in bovine plasma—substantially lower than the 80–90% observed for sulfadimethoxine—resulting in a larger free fraction available for glomerular filtration. Consequently, elimination half-life in swine averages 3–4 hours, necessitating divided daily dosing but simultaneously enabling shorter tissue withdrawal periods when compared to longer-residing pyrimidine sulfonamides. Crystalluria risk, a well-documented adverse effect of sulfathiazole therapy, arises from the limited urinary solubility of the acetylated metabolite at pH values below 6.0; this mandates that formulation excipients maintain alkaline urinary output or that concomitant water intake be guaranteed when high-dose regimens are employed.
Bulk active pharmaceutical ingredient (API) released onto EU and U.S. markets must conform to compendial monographs, though dedicated Sulphathiazole Sodium monographs are no longer active in USP and instead exist within the Sulphathiazole parent monograph with a sodium salt specific assay when intended for parenteral use. The European Pharmacopoeia (Ph. Eur.) historical monograph and the British Pharmacopoeia (Veterinary) volume provide the most granular specifications. A summary of the core quality attributes and their acceptance criteria drawn from these documentary standards is tabulated below.
| Attribute | Ph. Eur. / BP (Vet) | USP (Sulphathiazole, Sodium) | Test Method Reference |
|---|---|---|---|
| Assay (anhydrous basis) | 99.0–101.0% | 98.5–101.5% | HPLC (C18, UV 254 nm) / Nitrite titration |
| Identification | IR spectrum vs. CRS; sodium flame test | IR; TLC; melting point of free acid derivative 202–207°C | Ph. Eur. 2.2.24, USP <197> |
| Appearance of solution | Clear, not more intensely coloured than reference solution Y6 or GY6 | Not specified | Ph. Eur. 2.2.2 |
| pH (10% w/v aqueous) | 8.0–10.0 | 8.0–10.0 | Potentiometry, Ph. Eur. 2.2.3 |
| Related substances (HPLC) | Sulfanilamide ≤ 0.5%; any other impurity ≤ 0.5%; total ≤ 1.0% | Total impurities ≤ 1.0% | Ph. Eur. 2.2.29 |
| Loss on drying | 4.5–5.5% (monohydrate at 105°C) | ≤ 1.0% (anhydrous form, 105°C, 2 h) | Ph. Eur. 2.2.32 |
| Heavy metals | ≤ 20 ppm | ≤ 20 ppm | Ph. Eur. 2.4.8 |
The sodium salt crystallises predominantly as a monohydrate; loss on drying values outside 4.5–5.5% indicate incomplete hydration or desolvation during storage at elevated temperature. In-house quality agreements between API producers and feed-mill premix manufacturers often impose an internal particle size ceiling—D90 ≤ 150 µm by laser diffraction (ISO 13320)—to ensure blend uniformity in low-dose (0.5–2.0 kg per metric ton) final medicated feeds. Residual solvent headspace GC-MS screening per USP <467> is applied when the final synthetic step employs isopropyl alcohol or acetone as recrystallisation media.
In solid oral drug products formulated for dissolution in the upper gastrointestinal tract, API particle size and crystal habit become rate-determining performance variables. A rotating paddle apparatus (USP <711> Apparatus 2) operated at 50 rpm in 900 mL of pH 1.2 simulated gastric fluid (without enzyme) demonstrates that a mean dissolved fraction of ≥ 80% (Q = 75%) at 30 minutes is attainable for immediate-release bolus formulations when micronised sulphathiazole sodium exhibiting a D90 below 75 µm is embedded in a rapidly disintegrating matrix of microcrystalline cellulose and croscarmellose sodium. Published single-point dissolution specifications are product-specific; the pharmacopoeial API monograph does not prescribe an intrinsic dissolution rate. Manufacturers establishing in vitro-in vivo correlations (IVIVC) for extended-release rumen devices must consider the pH-dependent ionisation that shifts dissolution velocity as the dosage form transits from the abomasal (pH ~3) to the intestinal (pH ~6.8) environment. Temperature sensitivity of the dissolved free base’s solubility near 37°C necessitates that dissolution media be maintained within ±0.5°C across the test interval to keep data within repeatability limits (RSD ≤ 5.0% at the Q time point).Hygroscopic equilibration data generated on a dynamic vapour sorption (DVS) microbalance reveal that Sulphathiazole Sodium monohydrate gains less than 0.5% mass in the 20–60% RH range at 25°C but absorbs > 2.0% moisture when exposed to environments exceeding 70% RH. The resulting surface dissolution-recrystallisation bridging produces agglomerates that elevate the Hausner ratio from 1.15 (free-flowing) to beyond 1.40 (cohesive) within 48 hours of storage in a non-barrier package. Powder flow function coefficient (ffc), measured on a ring shear tester under 3 kPa pre-shear normal stress, declines from 6.0 to 2.8 under the same conditions, transitioning from easy-flowing to cohesive behaviour per ASTM D6128. To counteract this drift, blending directions commonly stipulate pre-drying at 60°C for 2 hours in a fluid-bed dryer followed by immediate transfer to a twin-shell V-blender (capacity 600–2000 L) maintained at ≤ 40% RH. Incorporation of fumed silica (colloidal silicon dioxide) at 0.5–1.0 wt% as a flow aid restores the Hausner ratio to ≤ 1.25. Extended blending beyond 15 minutes, however, induces electrostatic charging on the silica particles and causes de-mixing of the low-density API; validated mixing intervals cluster between 8 and 12 minutes at 15 RPM for 65% vessel fill. Forced-air cooling jackets on the blender shell have proven effective at pilot scale to dissipate frictional heat that otherwise accelerates hydrate water loss and alters the crystal surface energy.
The aqueous solubility gap between the sodium salt and the free acid under neutral conditions dictates formulation route selection. Sulphathiazole base exhibits a temperature-dependent aqueous solubility of approximately 0.6 mg·mL−1 at 25°C and 1.3 mg·mL−1 at 37°C, rendering suspension-based oral liquids difficult to standardise for dose. The sodium salt, by contrast, dissolves to at least 500 mg·mL−1 in water at 20°C, enabling true-solution drench formulations dosed at 200–400 mg·mL−1 for calves and lambs. At these concentrations, dynamic viscosity measured at 25°C (Brookfield LVDV, spindle 2, 60 RPM) can exceed 12 mPa·s, necessitating the addition of 10–15 v/v% propylene glycol (Ph. Eur. grade) to shear-thin the vehicle and improve pourability in cold-chain field conditions. A critical process conflict arises upon dilution in the ruminant stomach: ruminal fluid pH (5.5–6.8) partially protonates the sulfonamide anion, generating transient supersaturation before precipitation of the poorly wettable free acid crystals. To mitigate this, drench formulations frequently include polysorbate 80 (0.2–0.5% w/v) as a wetting agent and a pH–stat excipient such as trisodium citrate dihydrate to buffer the immediate dilution volume above pH 7.5. Accelerated stability studies (40°C, 75% RH for 6 months) in amber PET bottles confirm that photodegradation—tracked by the increase in sulfanilamide-related impurity B—lags behind thermal degradation provided the pack headspace is sparged with nitrogen to maintain dissolved oxygen below 2 ppm.
In parenteral presentations, the high solubility of the sodium salt obviates the need for co-solvents but imposes a narrow alkaline pH window (8.5–9.5) that, if exceeded during terminal sterilisation (autoclaving at 121°C for 15 minutes), accelerates hydrolytic cleavage of the sulfonamide bond. Post-sterilisation pH monitoring must confirm a drift < 0.3 units. Precipitation upon dilution with isotonic saline for intravenous administration is a recognised incompatibility when infusion solutions contain calcium or magnesium ions; a filter test through a 0.45 µm membrane is recommended before line connection. The combination with trimethoprim—a diaminopyrimidine—is the most common synergistic pairing, exhibiting a potentiated activity ratio of 1:5 (trimethoprim:sulphathiazole) in injectable products licensed for bovine respiratory disease, where batch release criteria demand an HPLC purity for both actives within 95.0–105.0% of label claim.
Differential scanning calorimetry (DSC) of anhydrous Sulphathiazole Sodium, run at a heating rate of 10 K·min−1 under nitrogen purge, exhibits a sharp melt endotherm with onset at 252 ± 2°C, immediately followed by exothermic decomposition above 260°C. When the monohydrate is analysed, a broad endothermic dehydration event centred at 110–130°C precedes the melt. Binary mixtures with reducing sugars—specifically lactose monohydrate and anhydrous dextrose—show a Maillard-type interaction onset near 70°C at moisture contents exceeding 5%, confirmed by darkening and a detectable increase in 5-hydroxymethylfurfural (HMF) by HPLC. This reaction excludes the application of hot-melt agglomeration or hot-air fluid-bed granulation without strict dew-point control of the inlet air (dew point ≤ +4°C). Magnesium stearate, a near-universal lubricant, forms stubborn pale-yellow complexes with the free amine degradation product, causing progressive mottling of tablet surfaces during long-term ICH stability storage (25°C/60% RH). Alternative lubrication with stearic acid (1.0% w/w) or sodium stearyl fumarate (0.5–1.5% w/w) has been adopted in half of the commercial batches audited to eliminate this interaction.
The choice between roller compaction (dry granulation) and direct compression for oral tablet production involves a polymorphic stability gate. Roller compaction at specific hydraulic pressures above 10 kN·cm−1 has been observed via X-ray powder diffraction (XRPD, Cu Kα radiation, 2θ range 5–40°) to generate a partially amorphous phase that recrystallises over 3 months at accelerated conditions to a densified mixed hydrate form, causing tablet hardness to rise by 30–40% and dissolution to slow beyond acceptance criteria. Direct compression avoids this transition but demands a feed powder with D10 ≥ 30 µm and D90 ≤ 180 µm to avoid segregation in the hopper of a high-speed rotary press (e.g., Fette 2200i, 47 stations, operating at 60–90 RPM). Blend uniformity analysis by stratified sampling from the press feed-frame must meet RSD ≤ 5.0% per USP <905>. A process control dilemma emerges when reducing tablet weight to accommodate low-dose (50 mg sulphathiazole per unit) veterinary applications: the excessively small die cavity (4 mm diameter) elevates ejection forces and laminate capping tendency unless microcrystalline cellulose grade is shifted to a highly compressible silicified variant (e.g., Prosolv® SMCC 90).Forced degradation studies conducted under ICH Q1B conditions (exposure to 1.2 million lux·hours visible light and 200 Wh·m−2 UV radiation in a Suntest CPS+ chamber) identify a primary photodegradant at relative retention time 0.72 versus the sulphathiazole peak, identified by LC-MS/MS as 4-aminobenzenesulfonamide (sulfanilamide). The quantum yield of this photolysis in aqueous solution at pH 9.0 is approximately 0.03 mol·Einstein−1, higher than that of sulfadiazine sodium under identical conditions. As a consequence, bulk API intended for packaging in translucent LDPE liners must be shipped in aluminium-laminated fibre drums, and oral liquid drench containers are required to incorporate a 2–3% (w/w) titanium dioxide (E171) opacity layer or be manufactured from amber PET meeting light transmission limits ≤ 10% at 450 nm per Ph. Eur. 3.2.2. Store humidity ranges mirror general warehouse norms (15–30°C), yet excursions above 30°C in combination with direct solar exposure reduce shelf life from 36 months to 12 months based on sulfanilamide growth exceeding the 0.5% threshold.
Sulphathiazole Sodium, when contrasted with sulfamethazine—the most widely used feed-grade sulfonamide in swine production—exhibits a faster elimination profile but also a narrower therapeutic index concerning nephrotoxicity. Sulfamethazine clearance in market-weight hogs demands a 15-day withdrawal period (EU MRL 100 µg·kg−1 for muscle), whereas sulphathiazole, due to its 3–4 hour half-life, can comply with a 7–10 day withdrawal under the same MRL frame, provided that water medication or top-dressing protocols guarantee homogeneous intake. However, the lower activity against certain Gram-negative enteric pathogens (MIC90 of 64 µg·mL−1 for Escherichia coli field isolates versus 32 µg·mL−1 for sulfachlorpyridazine) confines sulphathiazole’s current application to Gram-positive spectrum indications where resistance surveillance confirms below-threshold prevalence. The acid dissociation constant, crystal hydration states, and blend rheology collectively define the process envelope; deviations from the pharmacopoeial sodium salt monograph, particularly in loss on drying and pH of solution, cascade into downstream granulation failure modes and dissolution non-compliance. Operational boundaries established across multiple contract manufacturing sites fix the active pharmaceutical ingredient’s LOD at 4.8–5.2%, particle size D50 at 60–90 µm, and the direct-compression blend lubricant contact window at ≤ 5 minutes prior to compression—all monitored as in-process control parameters without which batch-to-batch dissolution variability exceeds tolerable limits.
